Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106295 · ClinicalTrials.gov registry record · Phase 2
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
A Phase 2 study of Mild Autonomous Cortisol Secretion (MACS) and Autonomous Cortisol Secretion, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06106295: Active Phase 2 study of Mild Autonomous Cortisol Secretion (MACS) and Autonomous Cortisol Secretion, sponsored by Mayo Clinic.
NCT06106295 is a Phase 2 study of Mild Autonomous Cortisol Secretion (MACS) and Autonomous Cortisol Secretion that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06106295, a Phase 2 study of Mild Autonomous Cortisol Secretion (MACS) and Autonomous Cortisol Secretion, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
Primary Outcome
Number of participants to experience adverse events
Conditions Studied
Interventions
- DRUG Metyrapone
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 2 |
What the registry record for NCT06106295 still lists
NCT06106295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Mild Autonomous Cortisol Secretion (MACS) appearing as the primary indexed condition, and to 1 intervention - of which Metyrapone is the first listed.
NCT06106295 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06106295 about?
NCT06106295 is a clinical study titled "Metyrapone for Mild Autonomous Cortisol Secretion (MACS)". The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
What is the current status of trial NCT06106295?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-12-19. Estimated completion is 2028-02-01.
What conditions does trial NCT06106295 study?
This clinical trial studies the following conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion.
What interventions are being tested in trial NCT06106295?
The interventions under investigation include: Metyrapone (DRUG).
Who is sponsoring clinical trial NCT06106295?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106295 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Autonomous Cortisol Secretion (MACS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06106295's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI